Pneumococcal Serotype Escape & Universal Vaccine Lab

🔬 Nasopharyngeal Micro-Arena

Epithelial Colonization & Opsonophagocytosis

Gen / Step:0 / 50 Total CFU:200 Vaccine Covered:68.5% Non-Vaccine Escape:31.5% Conserved Titer:0.00 ug/mL Clearance Rate:0.0%

Vaccine Preset:

Vaccine-Targeted Capsular Strains

Non-Vaccine Escape Strains

Macrophages / Opsonins

📊 Longitudinal Population Telemetry (D3.js)

Selective Pressure vs Pan-Protective Clearance

Serotype Composition (% Population) PCV-Target vs Escape Strain

Phagocytic Clearance & Protection Index Cumulative Rate

Vaccine Formulation PCV13

Capsule Conjugate Titer (IgG anti-CPS) 1.25 µg/mL

Universal Conserved Protein Cocktail (PspA/PsaA/CbpA) 0.00 µg/mL

Phagocyte Recruitment & Complement Activation 1.0x

Targeted Capsular Serotypes in Vaccine:

Immunology Evidence Ledger

Initial PCV Coverage: 68.5%

Gen 50 NV Strain Prevalence: 91.2%

Serotype Escape Evident: TRUE

Pan-Protein Cross-Clearance: 98.4%

Niche Filling Alert: When PCV13 selectively eliminates targeted capsular strains (e.g. 6B, 14, 19F), competitive inhibition in the nasopharynx drops, allowing unencapsulated or non-vaccine serotypes (e.g. 15A, 35B) to expand and dominate the open biological niche.

Translational Strategy

Recommended: Conserved protein antigen cocktail (PspA + PsaA + CbpA) to prevent niche filling by non-vaccine serotypes.

Population Dynamics Telemetry Export